| Source publication date | |
|---|---|
| Reported on Testosterone Science | |
| Outlet type | Testosterone and hormone clinic or telehealth website |
| Population | Men |
| Source | FYRE Body |
| URL | fyrebody.com/blogs/news/11-million-men-on-trt-why-americas-testosterone-revolution-is-just-getting-started (opens in a new tab) |
Specific Claim Evaluated
Average male testosterone has declined about 1% per year for decades, so that a 30-year-old today may have the testosterone level of his grandfather at age 50; enclomiphene is offered as an 'Oral Testosterone Program' that maintains fertility.
Primary Research Supporting or Contradicting the Claim
The 1% estimate comes from 1 cohort of men aged 45 to 79 years observed from 1987 to 2004 (Travison et al., 2007); NHANES data from 2011 to 2023 show a decline in the prevalence of low testosterone (Goulian et al., 2026). Enclomiphene evidence is limited to small trials with surrogate end points (Kaminetsky et al., 2013).
Corrected Evidence-Based Interpretation
No dataset supports the grandfather comparison. Enclomiphene is a selective estrogen receptor modulator, not testosterone, and is not FDA approved.
Rationale for Grade
The generational comparison is an extrapolation with no source, used to prompt readers to self-identify as testosterone deficient through a nonspecific symptom checklist. Labeling enclomiphene as an oral testosterone program misrepresents the drug. The article cites news reports but no research supporting its key claims.
References
- Goulian AJ, Ashkezari A, Eleswarapu SV. Unmasking masculinity: biological, behavioral, and social determinants of testosterone deficiency in U.S. men, 2011-2023. Am J Mens Health. 2026;20(2):15579883261433808. PMID
Supporting excerpt: "Testosterone deficiency is shaped by metabolic, behavioral, and relational factors" - Kaminetsky J, Werner M, Fontenot G, Wiehle RD. Oral enclomiphene citrate stimulates the endogenous production of testosterone and sperm counts in men with low testosterone: comparison with testosterone gel. J Sex Med. 2013;10(6):1628-1635. PMID
Supporting excerpt: "phase IIB study in 12 men with secondary hypogonadism" - Travison TG, Araujo AB, O'Donnell AB, Kupelian V, McKinlay JB. A population-level decline in serum testosterone levels in American men. J Clin Endocrinol Metab. 2007;92(1):196-202. PMID
Supporting excerpt: "a substantial, and as yet unrecognized, age-independent population-level decrease in T"